Who
Akos Czibere
Chief Medical Officer
Company insider
Files Form 4 as: Chief Medical Officer, Aktis Oncology.
In numbers
- Trades disclosed
- 18
- Buys
- 0
- Sells
- 2
- Bought
- $0
- Sold
- $3.3M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 8 Jul 2026
- Last trade
- 23 Sep 2026
- Last filed
- 24 Sep 2026
Companies traded
Activity over time
1 Jul – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 23 Sep 2026filed 24 Sep 2026 | AKTS Aktis OncologyBiotechnology | SEC FORM 4 Code M | $62K12,500 at $4.95 | filing |
| 23 Sep 2026filed 24 Sep 2026 | AKTS Aktis OncologyBiotechnology | SEC FORM 4 Sold | $103K5,099 at $20.19 | filing |
| 23 Sep 2026filed 24 Sep 2026 | AKTS Aktis OncologyBiotechnology | SEC FORM 4 Sold | $156K7,401 at $21.03 | filing |
| 23 Sep 2026filed 24 Sep 2026 | AKTS Aktis Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code M | —12,500 at $0.00 | filing |
| 23 Sep 2026filed 24 Sep 2026 | AKTS Aktis Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code M | —12,500 at $0.00 | filing |
| 23 Sep 2026filed 24 Sep 2026 | AKTS Aktis OncologyBiotechnology | SEC FORM 4 Code M | $62K12,500 at $4.95 | filing |
| 23 Sep 2026filed 24 Sep 2026 | AKTS Aktis OncologyBiotechnology | SEC FORM 4 Sold | $103K5,099 at $20.19 | filing |
| 23 Sep 2026filed 24 Sep 2026 | AKTS Aktis OncologyBiotechnology | SEC FORM 4 Sold | $156K7,401 at $21.03 | filing |
| 8 Jul 2026filed 10 Jul 2026 | AKTS Aktis OncologyBiotechnology | SEC FORM 4 Code M | $248K50,000 at $4.95 | filing |
| 8 Jul 2026filed 10 Jul 2026 | AKTS Aktis OncologyBiotechnology | SEC FORM 4 Sold | $401K14,800 at $27.13 | filing |
| 8 Jul 2026filed 10 Jul 2026 | AKTS Aktis OncologyBiotechnology | SEC FORM 4 Sold | $862K30,829 at $27.95 | filing |
| 8 Jul 2026filed 10 Jul 2026 | AKTS Aktis Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code M | —50,000 at $0.00 | filing |
| 8 Jul 2026filed 10 Jul 2026 | AKTS Aktis OncologyBiotechnology | SEC FORM 4 Sold | $125K4,371 at $28.71 | filing |
| 8 Jul 2026filed 10 Jul 2026 | AKTS Aktis Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code M | —50,000 at $0.00 | filing |
| 8 Jul 2026filed 10 Jul 2026 | AKTS Aktis OncologyBiotechnology | SEC FORM 4 Code M | $248K50,000 at $4.95 | filing |
| 8 Jul 2026filed 10 Jul 2026 | AKTS Aktis OncologyBiotechnology | SEC FORM 4 Sold | $402K14,800 at $27.13 | filing |
| 8 Jul 2026filed 10 Jul 2026 | AKTS Aktis OncologyBiotechnology | SEC FORM 4 Sold | $862K30,829 at $27.95 | filing |
| 8 Jul 2026filed 10 Jul 2026 | AKTS Aktis OncologyBiotechnology | SEC FORM 4 Sold | $125K4,371 at $28.71 | filing |
News
PTC Therapeutics (NASDAQ:PTCT) & Aktis Oncology (NASDAQ:AKTS) Head to Head ContrastAKTS · dailypolitical.com · 19 Oct 2026Reviewing Aktis Oncology (NASDAQ:AKTS) and Oncocyte (NASDAQ:IMDX)AKTS · tickerreport.com · 7 Oct 2026Critical Survey: Aktis Oncology (NASDAQ:AKTS) vs. Bicycle Therapeutics (NASDAQ:BCYC)AKTS · dailypolitical.com · 7 Oct 2026
0 headlines in the last 90 days name Akos Czibere; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.